Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma

ARNULF MAYER¹, FABIENNE SCHNEIDER¹, PETER VAUPEL¹, CLEMENS SOMMER² and HEINZ SCHMIDBERGER¹

Departments of ¹Radiooncology and Radiotherapy and ²Neuropathology, University Medical Center, D-55131 Mainz, Germany

Received April 9, 2012; Accepted June 1, 2012

DOI: 10.3892/ijo.2012.1555

Abstract. Hypoxia is an important factor mediating tumor progression and therapeutic resistance, in part through proteome changes mediated by the transcription factor hypoxia-inducible factor (HIF)-1. Since glioblastoma multiforme is the epitome of a highly aggressive tumor entity, while lower-grade astrocytomas often show a prolonged clinical course, a profound difference in the extent of hypoxic tissue areas and corresponding magnitude of HIF-1 activity may exist between these entities. In this study, to address this question, serial sections of 11 glioblastomas and 10 anaplastic astrocytomas were immuno-stained for HIF-1α, glucose transporter (GLUT)-1, carbonic anhydrase (CA) IX (i.e., hypoxia-related markers), Ki67 (proliferation), phosphorylated ribosomal protein S6 [p-rpS6; mammalian target of rapamycin (mTOR) activity] and CD34 (microvascular endothelium). Digital scans of whole tumor sections were registered to achieve geometric correspondence for subsequent morphometric operations. HIF-1α-, GLUT-1- and CA IX-positive staining was found in all 11 glioblastomas, showing a preferential expression in tissue areas adjacent to necroses. A considerable spatial overlap between GLUT-1 and CA IX, and a colocalization of these proteins with areas of enlarged mean diffusion distances were observed. Conversely, 8 of the 10 anaplastic astrocytomas were completely negative for hypoxia-related markers. The glioblastomas also showed significantly greater heterogeneity of intercapillary distances, larger diffusion-limited tissue fractions, significantly higher mTOR activity and a trend for higher proliferation rates. Microrregionally, mTOR and proliferation showed a significant spatial overlap with areas of shorter mean diffusion distances. In conclusion, diffusion-limited hypoxia, leading to the expression of hypoxia-related markers is a pivotal element of the glioblastoma phenotype and may be driven by dysregulated growth and proliferation in normoxic subregions.

Introduction

The transition from anaplastic astrocytoma (WHO grade III) to glioblastoma multiforme (WHO grade IV) is associated with a substantial increase in growth rate (1), tumor aggressiveness and resistance to therapy. While there is a meaningful proportion of patients with grade III tumors who survive for 5 years or more (2), prognosis becomes drastically poorer once the conversion to grade IV has taken place (3). For this reason, biological mechanisms behind this change in the disease course are of high interest. Hypoxia has been shown to play an important role in the malignant progression of various tumor entities (4) and, therefore, represents a candidate mechanism of this type. Both polarographic oxygen microelectrode measurements (5–10) and studies carried out with the exogenous hypoxia marker, 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-penta-fluoropropyl)-acetamide (EF5) (8), have shown that malignant astrocytomas do indeed contain a significant fraction of hypoxic tissue areas. Since hypoxia leads to the activation of the transcription factor hypoxia-inducible factor (HIF)-1 via stabilization of its α-subunit, the aforementioned results are supported by a number of studies which have indicated a widespread expression of HIF-1α (11–15) and its target genes glucose transporter (GLUT)-1 (16) and carbonic anhydrase (CA) IX (16,17), in malignant astrocytomas. However, most of these data do not refer exclusively to grade IV tumors, but instead suggest that hypoxic tissue areas may be prevalent even in low-grade gliomas. This is particularly true for studies using oxygen microelectrodes, which were unable to discriminate between low- and high-grade tumors. Studies of endogenous markers have in part shown a proportionality between the extent of marker expression and tumor grade (11,16,18). However, arguably, EF5 is the only surrogate marker of brain tumor hypoxia, for which a clear-cut difference between grades III and IV tumors has been identified. In a study which used both polarographic microelectrodes and EF5 to investigate the oxygenation status of grade II to IV astrocytomas (8), tumors of higher grades generally showed more abundant EF5 binding and, more importantly, quantities of EF5 corresponding to
severe tumor hypoxia (approximately 0.1% oxygen) were only found in grade IV tumors.

There is currently no consensus data available regarding the question as to which of these assays can assess hypoxia most accurately. Principally, hypoxia may result from increased diffusion distances, inadequate blood flow or increased oxygen consumption rates or any combination of these factors. However, very few studies have specifically investigated these parameters in malignant astrocytomas. Among these, Rijken et al (19) used a glioblastoma xenograft mouse model to examine the relationship between microvessel distribution, perfusion (Hoechst 33342) and hypoxia (using the exogenous marker pimonidazole). In this experimental setting, hypoxia was caused primarily by enlarged diffusion distances, as the extent of hypoxia was found to be inversely proportional to the density of perfused microvessels. Additionally, hypoxic areas were found beyond O2 diffusion distances larger than 60 to 80 µm from the nearest perfused microvessels. Furthermore, Brat et al (20) presented data indicating that acute, perfusion-limiting hypoxia may also play a role in glioblastoma, as areas of necrosis, a histological hallmark of this tumor type, often contain remnants of microvessels which show signs of intravascular thrombosis. Finally, using serial contrast-enhanced enhanced MRI and [18F]-fluoromisonidazole positron emission tomography (PET) studies, Szeto et al (21) were able to show a direct correlation between tumor proliferation and the severity of hypoxia, demonstrating the impact of increased oxygen consumption. The integration of growth factor signaling and nutrient availability is physiologically accomplished by mammalian target of rapamycin (mTOR), an evolutionary conserved serine/threonine kinase, which regulates protein translation. It has been previously demonstrated that hypoxia can inhibit mTOR activity (22), thereby avoiding the metabolic depletion of available oxygen to the point where hypoxia becomes limiting for oxidative phosphorylation (a strategy, which has been referred to as ‘oxygen conformance’) (23). In glioblastoma, this protective mechanism may at least partially be abrogated by overactive phosphoinositide-3-kinase (PI3K)-AKT signaling (24,25), which is an important upstream positive regulator of mTOR.

Additionally, a previous study established a direct link between mTOR activity and HIF-1α protein abundance (26). However, to the best of our knowledge, no study has thus far specifically addressed the relative contributions of these mechanisms and their correlations with each other in malignant astrocytomas, especially in human subjects. Therefore, the present study was carried out to address this question and, thereby, to contribute to the possible identification of the differences between the oxygenation status of anaplastic astrocytomas and glioblastomas. We investigated the expression pattern and intensity of endogenous markers of acute and chronic hypoxia (HIF-1α, GLUT-1 and CA IX), proliferation (Ki67) and mTOR status (using an antibody against the ribosomal protein S6 phosphorylated on serines 235/236 (p-rpS6) as a surrogate marker) in surgical resection specimens of 10 anaplastic astrocytomas and 11 glioblastomas. Using computer-aided image registration and analysis, the correlation of these markers with each other and with parameters derived from the abundance and location of CD34-positive tumor microvessels was analyzed.

Materials and methods

Samples and tumors. Histological sections of 11 glioblastomas and 10 anaplastic astrocytomas were obtained from the archive of the Department of Neuropathology, University Medical Center, Mainz, Germany. Other than tumor grade, no patient data were evaluated. The study was approved by the local medical ethics committee (Landesärztekammer Rheinland-Pfalz).

Immunohistochemistry. Histological slides were prepared from paraffin blocks and dried overnight at 37°C. The following day, specimens were dewaxed in 2 changes of fresh xylene and then rehydrated in a descending alcohol series. The retrieval of antigenic binding sites was carried out by heating specimens in appropriate buffers (see Table I for details) in a steamer (Braun FS 10, Braun, Kronberg, Germany) for 40 min. The primary antibodies and incubation conditions used are also listed in Table I. Two different detection systems were applied: biotin-free micropolymer-based Vector ImmPRESS kits (Vector Laboratories, Burlingame, CA, USA) were used for GLUT-1, CA IX, Ki-67, CD34 and p-rpS6. HIF-1α was detected using the catalyzed signal amplification system (Dako CSA, Cat. no. K1500; Dako, Hamburg, Germany) to increase sensitivity. As the CSA system is biotin-based, endogenous biotin was blocked using prefabricated reagents from the same manufacturer (Dako, Cat. no. X0590). Preceding methodological experiments showed that endogenous biotin can lead to an unspecific staining component that is difficult to discriminate from the true antigen reactivity when this step is omitted (data not shown). In the case of the micropolymer-based procedure (Vector ImmPRESS), the reagents were applied for 90 min at room temperature. Immunodetection with the Dako CSA system (HIF-1α) was carried out following the manufacturer’s instructions, except that all reagents were brought to a temperature of exactly 25°C using an Eppendorf Thermomixer compact (Eppendorf, Hamburg, Germany) before application. Negative control specimens were incubated in phosphate-buffered saline (PBS) without the primary antibody under the same conditions. Diaminobenzidine (DAB) was used as the peroxidase substrate. Slides were counterstained with Mayer’s hematoxylin, dehydrated in an ascending alcohol series, and covered with a coverslip using Eukitt mounting medium (Roti-Histokit; Carl Roth, Karlsruhe, Germany). Digital images of the specimens were acquired using a histology scanner (OpticLab H850, Plustek, Taipei, Taiwan). Additional images for illustration purposes were acquired using a microscopy (Axiolmager, Zeiss, Oberkochen, Germany) equipped with a digital camera (AxioCam HRC, Zeiss) connected to a Microsoft Windows-based PC running AxioVision (Zeiss), Photoshop CS4 (Adobe Systems Inc., San Jose, CA, USA) and ImageJ software (http://rsbweb.nih.gov/ij/).

Evaluation of immunostaining. Only immunostaining compatible with the known biological function and corresponding subcellular localization of each antigen was considered as being evaluable as marker expression (Table I). Notably, faint and often diffuse cytoplasmic staining for GLUT-1 and HIF-1α, which occurred in some areas of the tumors, was not assessed. Additionally, some tumor cells showed positivity for CD34,
which was not included in the calculation of microvessel-derived parameters.

*Image preparation and registration.* Scanned images of whole tumor sections stained for each antigen were examined simultaneously on the computer monitor to identify tumor regions which consistently contained viable tumor tissue and were present in acceptable quality for all antigens under investigation. Micronecroses within viable tumor tissue were considered acceptable, but all regions of gross necrosis were excluded from further analysis. Tumor regions discarded during this initial step were not included in any further analyses. Using different variations of the ‘lasso tool’ in Adobe Photoshop CS4, appropriate tumor areas were subsequently outlined in the CD34 image. To enable spatial correlations between different antigens and secondary parameters derived from them, digital images of scanned immunostains of HIF-1α, GLUT-1, CA IX, Ki67 and p-rpS6 were registered to the corresponding CD34 image. To achieve this, each source image (e.g., HIF-1α) and the corresponding target image (CD34) were opened simultaneously in ImageJ. Using the ‘multipoint tool’, approximately 50 to 200 corresponding landmarks were set in each image. The point selection was then converted to a ‘region of interest’ (ROI) and saved to a disk for later reference. Using the plugin ‘bunwarpj’ [http://fiji.sc/wiki/index.php/BUnwarpJ, (27)] both images were registered using the following parameters: registration mode, ‘mono’; initial deformation, ‘fine’; final deformation, ‘super fine’, landmark weight = 1, image weight = 1, verbose = yes. All other parameters were left at their default settings. The resulting mask was overlaid onto the original CD34 image and checked for plausibility. The resulting mask typically covered the entire vessel structure (Fig. 2a and b). A fourth step, the selection was converted to a binary B/W mask, which was transferred to ImageJ. Due to underthresholding, these masks often contained pixels in very close proximity to each other, which - upon comparison with the original CD34 image - can be identified as being part of identical vessel structures. Different approaches were tried to correct for this error (data not shown). The following procedure turned out to be the best compromise for the tumors studied in this study and was applied as a third step: first, 3 iterations of the ‘dilate’ command were applied, which were followed by the ‘fill holes’ procedure and 2 iterations of the ‘erode’ command, resulting in a net dilation of the vessel mask of one pixel. The resulting pixel mask was overlaid onto the original CD34 image and checked for plausibility. The resulting mask typically covered the entire vessel structure (Fig. 2a and b). In a fourth step, the binary mask was used to calculate the corresponding Voronoi tessellation, which is equivalent to the microvascular domains around each individual microvessel and deriving the diameter of a virtual circle of the same area, adapting the method of Yoshii and Sugiyama (28). The procedure involved the following steps: first, the positive pixels in the CD34 image were highlighted by color thresholding using the ‘wand tool’ in Adobe Photoshop CS4. We aimed to capture all CD34-positive pixels, but priority had to be given not to include any pixels which did not belong to CD34-positive blood vessels (e.g., debris, slight amounts of background staining), a strategy which may be referred to as ‘underthresholding’. In a second step, the selection was converted to a binary B/W mask, which was transferred to ImageJ. Due to underthresholding, these masks often contained pixels in very close proximity to each other, which - upon comparison with the original CD34 image - can be identified as being part of identical vessel structures. Different approaches were tried to correct for this error (data not shown). The following procedure turned out to be the best compromise for the tumors studied in this study and was applied as a third step: first, 3 iterations of the ‘dilate’ command were applied, which were followed by the ‘fill holes’ procedure and 2 iterations of the ‘erode’ command, resulting in a net dilation of the vessel mask of one pixel. The resulting pixel mask was overlaid onto the original CD34 image and checked for plausibility. The resulting mask typically covered the entire vessel structure (Fig. 2a and b). In a fourth step, the binary mask was used to calculate the corresponding Voronoi tessellation, which is equivalent to the microvascular domains around each separate microvessel (Fig. 2c). Since some blood vessels may occupy a considerable fraction of the area of their microvascular domain, area measurements of the latter were corrected by subtraction of the number of CD34-positive pixels from the total number of pixels in each area. Finally,

### Table I. Antibodies (ABs), immunohistochemical technique and resulting staining patterns.

| Antigen | Epitope retrieval buffer | Primary AB, Cat. no., dilution | Primary AB supplier | Detection system | Staining pattern |
|---------|--------------------------|-------------------------------|---------------------|-----------------|-----------------|
| HIF-1α  | Citrate, pH 6.0           | NB 100-123, 1:1000            | Novus Biologicals, Littleton, CO, USA | CSA, Dako       | Nuclear         |
| GLUT-1  | Citrate, pH 6.0           | G1817C01, 1:200               | DCS, Hamburg, Germany | ImmPRESS anti-rabbit vector | Membranous |
| CA IX   | Citrate, pH 6.0           | ab15086, 1:1000               | Abcam, Cambridge, UK | ImmPRESS anti-rabbit vector | Membranous |
| CD34    | Tris/EDTA, pH 9.0         | M7165, 1:50                   | Dako, Hamburg, Germany | ImmPRESS anti-mouse vector | Membranous |
| Ki67    | Tris/EDTA, pH 9.0         | ab16667, 1:200                | Abcam, Cambridge, UK | ImmPRESS anti-rabbit vector | Nuclear |
| p-rpS6  | Citrate, pH 6.0           | #4857, 1:75                   | Cell Signaling Technology, Danvers, MA, USA | ImmPRESS anti-rabbit vector | Cytoplasmic |

*aMonoclonal antibody, bpolyclonal antibody.*

*Estimation of intercapillary distances (ICDs).* ICDs were measured by determining the area of the ‘microvascular domain’ surrounding each individual microvessel and deriving the diameter of a virtual circle of the same area, adapting the method of Yoshii and Sugiyama (28). The procedure involved the following steps: first, the positive pixels in the CD34 image were highlighted by color thresholding using the ‘wand tool’ in Adobe Photoshop CS4. We aimed to capture all CD34-positive pixels, but priority had to be given not to include any pixels which did not belong to CD34-positive blood vessels (e.g., debris, slight amounts of background staining), a strategy which may be referred to as ‘underthresholding’. In a second step, the selection was converted to a binary B/W mask, which was transferred to ImageJ. Due to underthresholding, these masks often contained pixels in very close proximity to each other, which - upon comparison with the original CD34 image - can be identified as being part of identical vessel structures. Different approaches were tried to correct for this error (data not shown). The following procedure turned out to be the best compromise for the tumors studied in this study and was applied as a third step: first, 3 iterations of the ‘dilate’ command were applied, which were followed by the ‘fill holes’ procedure and 2 iterations of the ‘erode’ command, resulting in a net dilation of the vessel mask of one pixel. The resulting pixel mask was overlaid onto the original CD34 image and checked for plausibility. The resulting mask typically covered the entire vessel structure (Fig. 2a and b). In a fourth step, the binary mask was used to calculate the corresponding Voronoi tessellation, which is equivalent to the microvascular domains around each separate microvessel (Fig. 2c). Since some blood vessels may occupy a considerable fraction of the area of their microvascular domain, area measurements of the latter were corrected by subtraction of the number of CD34-positive pixels from the total number of pixels in each area. Finally,
the distribution of microvessel domain areas and the corresponding standard deviations were calculated in ImageJ and converted to the corresponding calibrated ICD values.

Calculation of diffusion-limited fractions (DLFs). To estimate the fraction of tissue experiencing chronic hypoxia, we calculated the extent of tumor area beyond a distance of...
Table II. Marker expression in glioblastoma vs. anaplastic astrocytoma.

| % of tumor area | Glioblastoma | Anaplastic astrocytoma | Difference p-value |
|-----------------|--------------|------------------------|-------------------|
|                 | Mean         | Range                  |                   |
| HIF-1α          | 1.3          | 0.1-4.9                | 0.001             |
| GLUT-1          | 8.7          | 0.5-15.9               | 0.00004           |
| CA IX           | 3.3          | 0.4-11.3               | 0.0004            |
| Ki67            | 3.9          | 0.1-10.1               | 0.0986            |
| p-rpS6          | 11.0         | 0.2-23.3               | 0.02416           |

80 and 120 µm to the nearest microvessel. Haustermans et al published a similar study on rectal cancer (29) and referred to this measure as the DLF. The choice of cut-off points for our study of malignant astrocytoma tissue was based on data from Rijken et al (19), who showed that the binding intensity of the exogenous hypoxia markers, pimonidazole and 7-(4-(2-nitroimidazol-1-yl)-butyl)-theophylline (NITP), in a human glioma xenograft model increased significantly beyond approximately 80 µm and reached their highest values beyond a diffusion distance of 100 µm. Additionally, Groebe and Vaupel (30) published calculated diffusion radii at the beginning (= arterial end) of tumor microvessels of similar magnitude. In detail, the CD34 pixel mask (see above) was used to calculate an Euclidean distance map, i.e., a gray level image of the exact same dimensions as the original CD34 image, in which the gray value of each pixel is directly proportional to its distance from the nearest microvessel within an 8-bit dynamic range. A gray value histogram of this image represents the distribution of diffusion distances in the original image. The fractions of the number of pixels above a calibrated distance of 80 and 120 µm were calculated and designated as DLF80 and DLF120, respectively.

Quantification of marker expression. The extent of the expression of HIF-1α, GLUT-1, CA IX, Ki67 and p-rpS6 was quantified as the positive fraction of the total evaluable tumor area. As a consequence of the registration procedure outlined above, the total tumor area in individual tumors was identical for all antigens. Marker-positive pixels were highlighted by color thresholding in Adobe Photoshop CS4 using the ‘wand tool’, while simultaneously examining the corresponding glass slides under the microscope to avoid capturing regions which did not belong to cancer cells. This was especially important in the case of GLUT-1, which is not only found in cancer cells but also exhibits a physiological expression in the endothelium of autochthonous brain capillaries and the cell membrane of red blood cells (31). The resulting selection was used to generate a B/W binary mask image which was saved to a file for colocalization analysis. In an analogous manner, mask images were generated for the total evaluable tumor area. Using ImageJ, the number of positive pixels per total tumor area was calculated.

Colocalization studies. Binary masks of HIF-1α, GLUT-1, CA IX, Ki67 and p-rpS6 generated in the previous step were used to investigate mutual colocalization patterns of these antigens. GLUT-1 was used as the reference for hypoxic tissue areas. To characterize the degree of overlap between individual markers we calculated an ‘overlap co-efficient’ (OC):

\[
OC = \frac{\text{pixels of marker A colocalizing with marker B}}{\text{pixels of marker B}}
\]

\[
OC = \frac{\text{pixels of marker A not colocalizing with marker B}}{\text{pixels of marker A not colocalizing with marker B}}
\]

In the case of a completely equal distribution of marker A within tumor areas positive for marker B, the value of \(OC = 1\). With increasing colocalization, the \(OC\) rises, while it falls below 1 in the case of increasing colocalization of marker A with areas negative for marker B. \(OC\) is not defined in the case of a perfect (i.e., 100%) colocalization.

Statistical analyses. All statistical analyses were performed using the SPSS software package (version 20, IBM, Armonk, NY). The significance level was set at \(\alpha = 5\%\) for all comparisons. Linear correlations between 2 variables were described by Spearman’s rank correlation coefficient (\(\rho\)). Two-sided Mann-Whitney U tests and Wilcoxon tests were used for comparison of categorized variables.

Results

Expression of hypoxia-related markers. All 11 glioblastomas were positive for all 3 hypoxia-related markers (HIF-1α, GLUT-1 and CA IX). Regions of micronecrosis were almost invariably surrounded by staining for GLUT-1 or partially surrounded by staining for the other 2 hypoxia-related markers, but staining of all 3 markers additionally occurred independent of necrosis (Fig. 3a-f). The extent of marker expression in individual tumors was highly heterogeneous. The expression of GLUT-1 was most abundant (Table II). Conversely, only 2 out of the 10 anaplastic astrocytomas showed expression of all three hypoxia-related markers, while the remaining 8 tumors were completely negative (Fig. 4a-f). The extent of GLUT-1 expression highly correlated with the expression of both HIF-1α (\(\rho=0.76, p<0.0001\)) and CA IX (\(\rho=0.87, p<0.0001\)). For all 3 markers, the difference in antigen expression between glioblastoma and anaplastic astrocytoma was highly significant (Table II).

mTOR activity and proliferation. Similar to hypoxia-inducible proteins, intertumor heterogeneity of proliferation and mTOR

\[
\text{mTOR activity and proliferation. Similar to hypoxia-inducible proteins, intertumor heterogeneity of proliferation and mTOR}
\]

\[
\text{mTOR activity and proliferation. Similar to hypoxia-inducible proteins, intertumor heterogeneity of proliferation and mTOR}
\]
activity was pronounced. mTOR activity (as assessed by the abundance of p-rpS6) was significantly higher in glioblastomas compared to anaplastic astrocytomas, while there was only a trend for higher proliferation (Ki67) in these tumors (Table II). Both markers were significantly more abundant in GLUT-1 positive tumors (mTOR: $\rho = 0.55$, $p<0.009$; Ki67: $\rho = 0.51$, $p<0.017$). Additionally, there was a correlation between the extent of p-rpS6 and Ki67 staining ($\rho = 0.59$, $p=0.005$).

ICD and DLF. Mean ICDs were slightly larger in glioblastomas compared to anaplastic astrocytomas, although this difference was not statistically significant. However, standard deviations of ICDs were found to be significantly different between these entities, with glioblastomas showing higher values ($p=0.02$, Fig. 5). Importantly, compared to anaplastic astrocytomas, glioblastomas showed significantly larger areas experiencing chronic hypoxia, as assessed by the parameters $DLF_{80}$ ($p=0.043$) and $DLF_{120}$ ($p=0.006$). For both parameters, the respective fractions of the tumor areas were approximately twice as large in glioblastomas compared to anaplastic astrocytomas (Fig. 5). The standard deviation of ICDs, $DLF_{80}$ and $DLF_{120}$ also showed positive correlations with GLUT-1 ($q=0.51$, $q=0.46$ and $q=0.58$, respectively, $p<0.05$) and HIF-1$\alpha$ ($q=0.48$, $q=0.44$ and $q=0.55$, respectively, $p<0.05$), while CA IX only correlated with $DLF_{120}$ ($q=0.52$, $p=0.016$).

Correlations between marker expression and diffusion distances. Point-to-point registration of all images to the CD34 reference image allowed the analysis of the distribution of diffusion distances in marker-positive vs. marker-negative areas. As expected, significantly higher mean diffusion distances were observed in GLUT-1 and CA IX-positive areas compared to the
corresponding marker-negative areas (p=0.003 for both). There was also a trend for higher mean diffusion distances in HIF-1α positive areas, but the level of statistical significance was not reached. Areas positive for the mTOR surrogate marker, p-rpS6, and the proliferation marker, Ki67, both contained significantly shorter mean diffusion distances compared to marker-negative areas (p=0.001 and 0.006, respectively) although the absolute magnitude of this difference was modest.

Colocalization analysis. In addition to the quantitative correlations described above, we also investigated the spatial colocalization of marker expression. As the aforementioned analyses had shown that GLUT-1 is the most abundant marker of chronic hypoxia, the latter was chosen as the reference marker for this purpose. The degree of colocalization between CA IX and GLUT-1 was very high, exhibiting a mean OC value of 64.1 (range, 3.1 to 340.6), (Fig. 6a). As CA IX staining was less extensive than GLUT-1 staining, regions of CA IX positivity were often found as subareas within the GLUT-1-positive areas. Only a partial colocalization was found between GLUT-1 and HIF-1α (mean OC = 5.9; range, 0 to 28.6), (Fig. 6b). Only parts of the GLUT-1-positive area were positive for HIF-1α and there were additional HIF-1α-positive regions in well-vascularized areas. Mean OC values for p-rpS6 and Ki67 were <1 (0.81 and 0.72, respectively), indicating a tendency for the expression outside of the hypoxic regions. The degree of this pattern was variable, with selected tumors showing almost a mirror-image pattern of the hypoxic regions (Fig. 6c and d). Of note, both the latter antigens displayed only a minor degree of colocalization with each other (mean OC = 1.98).
Discussion

In this study, we employed a novel approach using computerized image analysis of multiparametric immunohistochemistry in registered serial whole tumor sections to systematically investigate the hypoxia-related pathophysiology of glioblastoma and anaplastic astrocytoma. To the best of our knowledge, this is the first study clearly showing that glioblastomas and anaplastic astrocytomas exhibit significantly larger proportions of diffusion-limited tumor areas. As shown in Figure 5, glioblastomas exhibited a larger proportion of diffusion-limited tumor areas (*p=0.043; **p=0.006). AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; DLF, diffusion-limited fraction.

Figure 5. Comparison of microvessel-associated parameters in glioblastoma vs. anaplastic astrocytoma. (a) The distributions of mean values (ICD-M) and standard deviations (ICD-SD) of intercapillary distances of glioblastomas (n=11, grey) and anaplastic astrocytomas (n=10, white). Glioblastomas exhibited significantly larger standard deviations of intercapillary distances (*p=0.02). As shown in (b), glioblastomas exhibited a larger proportion of diffusion-limited tumor areas (*p=0.043; **p=0.006). AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; DLF, diffusion-limited fraction.

Figure 6. Colocalization analysis. 800x800 pixel selection from a glioblastoma showing merged images of GLUT-1 (red) and (a) CA IX, (b) HIF-1α, (c) Ki67 and (d) p-rpS6. The latter antigens are each shown in green. Yellow indicates colocalization. (a) GLUT-1 and CA IX exhibit substantial overlap. (b) HIF-1α expression is sparse and overlap is less evident. (c) Ki67 is preferentially located in GLUT-1-negative areas, while p-rpS6 shows a similar tendency but its expression is more pronounced in areas directly adjacent and even overlapping with GLUT-1-positive regions (d). Scale bar in (a) 500 µm.
astrocytomas differ fundamentally as regards the expression of the hypoxia-related markers, HIF-1α, GLUT-1 and CA IX. All of the investigated glioblastomas, but only 2 anaplastic astrocytomas were positive for all 3 of these proteins. By contrast, the remaining 80% of anaplastic astrocytomas were negative for all 3 hypoxia-related markers. This finding is consistent with a recent meta-analysis of mRNA expression, which showed that HIF-1α-mediated transcription occupied the highest rank among pathways which are more active in glioblastomas compared to anaplastic astrocytomas (32).

Since HIF-1α directly transactivates GLUT-1 and CA IX, our findings of concordant positivity and significantly correlated abundance of these proteins are consistent with theoretical considerations. Furthermore, the spatial distribution of the hypoxia-related proteins clearly showed a preference for the immediate vicinity of tissue necrosis, which is a well-known pattern described previously (15,33-35). This may suggest that necrosis, a pathognomonic sign of glioblastoma, is triggered by hypoxia; however, data supporting a role for alternative causative factors have also been reported [e.g., glucose depletion (36) and glutamate excitotoxicity (37)]. Differences in the quantitative expression levels of hypoxia-related markers in individual tumors, as observed in our study, are not surprising given the well-known fact that hypoxia-inducible proteins show substantial dissimilarities regarding magnitude (38) and the time course of induction by hypoxia as well as half-life upon re-oxygenation (39,40). Additionally, the influence of hypoxia may be modified by other variables of the tumor microenvironment [e.g., glucose availability (41)]. Similar variations between GLUT-1 and CA IX have been reported, e.g., in cancers of the uterine cervix (42).

A number of previous studies have already described an increase in the expression of the hypoxia-dependent proteins, HIF-1α, GLUT-1 and CA IX, with increasing malignancy grade [from grades II to IV] (11-13,17)]. However, this does not necessarily imply significant differences between grades III and IV, which were reported in only 2 of these studies (11,17). Surprisingly, a study by Flynn et al (16) not only showed a (non-significant) increase in GLUT-1 expression with tumor grade, but also reported a lower expression of CA IX in glioblastomas compared to anaplastic astrocytomas. Compared to our study, the prevalence of marker-positive cases in most of the aforementioned studies was far higher in terms of anaplastic astrocytomas (exceeding 50%) (11-13) and lower as regards glioblastomas (12,13,17). The following factors may be considered to explain these differences. First, marker expression in our study was analyzed in whole tumor sections, preventing false-negative results which may occur with smaller specimens due to the large heterogeneity of the expression of hypoxia-related markers. Second, assessment criteria of positivity of immunohistochemical staining were defined narrowly in our study. As described in the Materials and methods section, only a distinct, biologically justifiable staining at the level of individual cells was counted as a positive signal. Indeed, grade III tumors frequently exhibited cytoplasmic positivity for HIF-1α or GLUT-1. The intensity of this cytoplasmic signal, however, was on a far lower level compared to the specific signal which was observed (in the case of HIF-1α in tumor cell nuclei, in the case of GLUT-1 in the cell membrane of tumor cells, endothelial cells of autochthonous blood vessels of the brain and in erythrocytes). Third, we took methodological precautions to avoid artifacts that may arise from the false-positive staining of endogenous biotin. This source of error has been previously described as being relevant for rat brain tissues (43) and its relevance for human tissue has been documented by us in preliminary methodological experiments (data not shown). In the case of HIF-1α, which we detected with the extremely sensitive ‘catalyzed signal amplification’ system, we added additional steps to the protocol to actively block endogenous biotin. All other antigens were detected with a non-biotin-based detection system, for which this source of error does not play a role. The fact that our results quantitatively are both lower (as regards anaplastic astrocytomas) and higher (as regards glioblastomas) than other studies, argues against an overall inferior sensitivity of our immunohistochemical protocols.

As a second main result, we show that the proportion of tissue areas beyond diffusion distances of 80 and 120 μm (DLF80 and DLF120, respectively) is far greater in glioblastomas than in anaplastic astrocytomas. In keeping with this finding, the heterogeneity (i.e., standard deviation) of the mean ICDs in glioblastoma is also higher and GLUT-1- and CA IX-positive areas colocalize with areas of significantly higher mean diffusion distances. This substantial increase in diffusion distances (and possibly in hypoxic tissue areas) observed in our study, is consistent with the finding of an increase in the extent of EF5 binding in glioblastomas compared to anaplastic astrocytomas (8). Data on the quantification of the vasculature of glioblastoma are limited. Studies that have determined vascularization in so-called ‘hot spots’ (44), primarily investigate clinical utility as a prognostic parameter and may be compared only partially with the analysis described in our study. Quantitative approaches comparable to our study are found in the studies by Wesseling et al (45,46). These authors have also studied complete tumor sections of glioblastoma with the help of digital image analysis in comparison with normal brain white matter (46). In another study (45), astrocytomas of grade II to IV were compared to normal brain tissue. In both studies, it was shown that, similar to our results, glioblastomas exhibited a remarkably high standard deviation of all vascularization-associated parameters, which distinguished this entity from anaplastic astrocytomas and, in fact, all other entities examined. These studies also found an increased mean number, surface area, volume and diameter of the vessels examined in glioblastomas compared to lower grade gliomas and normal brain tissue. This observation does not contradict our data, since the parameters analyzed by us do not exclude the presence of a high number of vascular structures, but merely describe whether these structures are distributed in an uneven fashion, thereby leading to the occurrence of diffusion-limited areas. Furthermore, Yoshii and Sugiyama (28) showed decreased ICDS in gliomas (of different grades of malignancy) compared to normal white matter. Differences between their analysis and our study may primarily relate to a decisive difference in the sampling strategy. While our study excluded only macroscopic necrosis and performed an unbiased quantification on large tumor areas, Yoshii and Sugiyama investigated ICDS only in confined areas of high proliferation (as measured by bromodeoxyuridine staining). Additionally, Yoshii and Sugiyama (28) relied solely on visual identification of blood vessels in H&E.
While there is no doubt that mTOR can control proliferation outside of GLUT-1-positive areas. In selected cases is highly dysregulated in glioblastoma (24,25). Compatible consider that mTOR, an integration hub of both influences (22) of ‘outgrowing’ blood supply, it is of particular importance to availability of oxygen may be responsible for the phenomenon between endogenous and exogenous growth signals and the existence of a dual relationship between hypoxia and prolifera -tive activity in glioblastoma. On the one hand, the intensity of proliferation was correlated with the magnitude of GLUT-1 expression on a global level. On the other hand, colocalization analyses revealed that microregional Ki67 tended to cluster outside of GLUT1-positive areas. A global correlation between proliferation and GLUT-1 abundance, to our knowledge, has not been previously described in human glioblastoma, but has been reported for other tumor entities (48,49). Additionally, Zhong et al (33) described a correlation between higher proliferation and HIF-1α in 126 tumors of 13 entities. These data are commonly interpreted as being the result of a tumor, which exhibits a proliferation too high in relation to its angiogenic potency and this view is indeed compatible with the data of Brat et al (20) or differences in the blood flow of feeding arterioles. Technical imperfections may also play a role in these mismatches in individual cases. While the registration of serial sections was possible with high precision, the use of 4-µm-thick specimens, as employed in the present study, may lead to distances along the z-axis which cannot be fully compensated by morphological operations. In a few specimens, optimal thresholding of CD34-positive pixels also proved to be more difficult, since the tumor cells also showed a signal.

The third essential finding arising from our data is the existence of a dual relationship between hypoxia and proliferative activity in glioblastoma. On the one hand, the intensity of proliferation was correlated with the magnitude of GLUT-1 expression on a global level. On the other hand, colocalization analyses revealed that microregional Ki67 tended to cluster outside of GLUT1-positive areas. A global correlation between proliferation and GLUT-1 abundance, to our knowledge, has not been previously described in human glioblastoma, but has been reported for other tumor entities (48,49). Additionally, Zhong et al (33) described a correlation between higher proliferation and HIF-1α in 126 tumors of 13 entities. These data are commonly interpreted as being the result of a tumor, which exhibits a proliferation too high in relation to its angiogenic potency and this view is indeed compatible with the data of Brat et al (20) (see Introduction). As inadequate feedback between endogenous and exogenous growth signals and the availability of oxygen may be responsible for the phenomenon of ‘outgrowing’ blood supply, it is of particular importance to consider that mTOR, an integration hub of both influences (22) is highly dysregulated in glioblastoma (24,25). Compatible with this suspected pathophysiology, GLUT-1-positive tumors also showed an increased mTOR activity in our study. However, residual responsiveness of mTOR to oxygen deprivation may be mirrored by our finding of a preferential aggregation of p-rpS6 outside of GLUT1-positive areas. In selected cases this even corresponded to a nearly complementary pattern. While there is no doubt that mTOR can control proliferation in vitro, our in vivo finding of an at least partial decoupling of proliferation and mTOR in our colocalization analyses argues against a simple causal relationship between the dysregulation of mTOR and Ki67.

In conclusion, glioblastomas represent a tumor entity, which is shaped decisively by hypoxic tissue areas. Our results clearly show that the activation of hypoxia-induced protein expression is typically not observed in anaplastic astrocytomas. It therefore seems possible, even probable, that the minority of anaplastic astrocytomas which exhibit an activation of the hypoxic response biologically already represent the decompensated phenotype of glioblastoma. This is of great clinical interest, as it may represent a pathophysiological rationale for treatment of these patients, similar to glioblastoma.

Acknowledgements

H.S. indicates a ‘minor’ relationship with Roche Pharma AG due to his activity as a member of the data safety monitoring board of the study ‘GLARIUS’. This manuscript partly contains results from the doctoral thesis of F.S.

References

1. Swanson KR, Bridge C, Murray JD and Alvord EC Jr.: Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurosurg 216: 1-10, 2003.
2. Stupp R, Reni M, Gaita G, Mazza E and Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63: 72-80, 2007.
3. Sathersnumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularily targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
4. Vaupel P and Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239, 2007.
5. Kayama T, Yoshimoto T, Fujimoto S and Sakurai Y: Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 74: 55-59, 1991.
6. Ramplening R, Cruickshank G, Lewis AD, Fitzsimmons SA and Workman P: Direct measurement of PO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431, 1994.
7. Evans SM, Judy KD, Dunphy I, et al: Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64: 1886-1892, 2004.
8. Evans SM, Judy KD, Dunphy I, et al: Hypoxia is important in the biology and aggregation of human glial brain tumors. Clin Cancer Res 10: 8177-8184, 2004.
9. Collingridge DR, Piepmeier JM, Rockwell S and Knisely JP: Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53: 127-131, 1999.
10. Vaupel P, Höckel M and Mayer A: Detection and characterization of tumor hypoxia using PO2 histography. Antioxid Redox Signal 9: 1221-1235, 2007.
11. Korkolopoulou P, Patsouris E, Konstantinidou AE, et al: Hypoxia-inducible factor 1a/vascular endothelial growth factor axis in astrocytomas. Associations with microvesSEL morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30: 267-278, 2004.
12. Sonderegga KL, Hilton DA, Penney M, Ollerenshaw M and Demaine AG: Expression of hypoxia-inducible factor 1α in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 28: 210-217, 2002.
13. Mashiko R, Takano S, Ishikawa E, Yamamoto T, Nakai K and Matsumura A: Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 102: 43-50, 2011.
14. Birner P, Piribauer M, Fischer I, et al: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13: 133-143, 2003.
15. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW and Semenza GL: Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618, 2000.

16. Flynn JR, Wang L, Gillespie DL, et al: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 113: 1032-1042, 2008.

17. Yoo H, Sohn S, Nam BH, et al: The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis. Int J Mol Med 26: 3-9, 2010.

18. Giannopoulou E, Ravazoula P, Kalokaranis T and Kardamakis D: Expression of HIF-1α and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo 20: 421-425, 2006.

19. Rijken PF, Bernsen HJ, Peters JP, Hodgkiiss RJ, Raleigh JA and van der Kogel AJ: Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a qualitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48: 571-582, 2000.

20. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64: 920-927, 2004.

21. Szeto MD, Chakrabarty G, Hadley J, et al: Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRR with hypoxia assessed by FMISO-PET in newly diagnosed gliomas. Cancer Res 69: 4502-4509, 2009.

22. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 282: 29655-29660, 2007.

23. Wheaton WW and Chandel NS: Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol 300: C385-C393, 2011.

24. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.

25. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling core pathways. Nature 455: 1061-1068, 2008.

26. Thomas GV, Tran C, Mellinghoff IK, et al: pp85-95, 2006.

27. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278: 29655-29660, 2003.

28. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.

29. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.

30. Arganda-Carreras I, Sorzano C, Marabini R, Carazo J, Ortiz-de-Solorzano C and Kybic J: Consistent and elastic registration of histological sections using vector-spline regularization. In: Computer Vision Approaches to Medical Image Analysis. Beichel RR and Sonka M (eds). Springer, Berlin, Heidelberg, pp85-95, 2006.

31. Yoshii Y and Sugiyama T: Intercapillary distance in the prolife -

32. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278: 29655-29660, 2003.

33. Wheaton WW and Chandel NS: Hypoxia. 2. Hypoxia regulates cellular metabolism. Am J Physiol Cell Physiol 300: C385-C393, 2011.

34. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.

35. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.

36. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.

37. Arganda-Carreras I, Sorzano C, Marabini R, Carazo J, Ortiz-de-Solorzano C and Kybic J: Consistent and elastic registration of histological sections using vector-spline regularization. In: Computer Vision Approaches to Medical Image Analysis. Beichel RR and Sonka M (eds). Springer, Berlin, Heidelberg, pp85-95, 2006.

38. Yoshii Y and Sugiyama T: Intercapillary distance in the proliferating area of human glioma. Cancer Res 48: 2938-2941, 1988.

39. Haustermans K, Hofland I, van de Pavert L, et al: Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiother Oncol 55: 325-333, 2000.

40. Groebe K and Vauapel P: Evaluation of oxygen diffusion distances in human breast cancer xenografts using tumor-specific in vivo data: role of various mechanisms in the development of tumor hypoxia. Int J Radiat Oncol Biol Phys 15: 691-697, 1988.

41. Takata K: Glucose transporters in the transepithelial transport of glucose. J Electro Microsc (Tokyo) 45: 275-284, 1996.

42. Dreyfuss JM, Johnson MD and Park PF: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8: 71, 2009.

43. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.

44. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278: 29655-29660, 2003.

45. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.

46. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.

47. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278: 29655-29660, 2003.

48. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.

49. Yoshii Y and Sugiyama T: Intercapillary distance in the proliferating area of human glioma. Cancer Res 48: 2938-2941, 1988.

50. Haustermans K, Hofland I, van de Pavert L, et al: Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. Radiother Oncol 55: 325-333, 2000.

51. Groebe K and Vauapel P: Evaluation of oxygen diffusion distances in human breast cancer xenografts using tumor-specific in vivo data: role of various mechanisms in the development of tumor hypoxia. Int J Radiat Oncol Biol Phys 15: 691-697, 1988.

52. Takata K: Glucose transporters in the transepithelial transport of glucose. J Electro Microsc (Tokyo) 45: 275-284, 1996.

53. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.

54. Arsham AM, Howell JJ and Simon MC: A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278: 29655-29660, 2003.

55. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12: 882-889, 2010.

56. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127, 2006.

57. Arganda-Carreras I, Sorzano C, Marabini R, Carazo J, Ortiz-de-Solorzano C and Kybic J: Consistent and elastic registration of histological sections using vector-spline regularization. In: Computer Vision Approaches to Medical Image Analysis. Beichel RR and Sonka M (eds). Springer, Berlin, Heidelberg, pp85-95, 2006.